SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)

Concepts

• bristol
• immunoglobulins
• defence equipment and support
• botulism
• supply of botulism antitoxin heptevalent
• supply of heptavalent botulism antitoxin
• hbat
• part of defence equipment
• uk ministry of defence
• de&s

Location

Description

The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), has placed a contract with Emergent Biosolutions Canada Inc for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 3 years. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.

Award Detail

CPV Codes

• 33651520 - Immunoglobulins

Legal Justification

It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”. Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.

Other Information

** PREVIEW NOTICE, please check Find a Tender for full details. **